XERIS PHARMACEUTICALS INC

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: $429.1M

Website

Clinical Trials

Study of XP-8121 For the Treatment of Adult Subjects With Hypothyroidism

Phase 2

Completed

Conditions: Hypothyroidism

Interventions: Drug: levothyroxine sodium

First Posted Date: 2023-04-21

Last Posted Date: 2024-07-26

Lead Sponsor: Xeris Pharmaceuticals

Target Recruit Count: 46

Registration Number: NCT05823012

Locations: 🇺🇸
Panax Clinical Research, LLC, Miami Lakes, Florida, United States
🇺🇸
American Research Corporation, San Antonio, Texas, United States
🇺🇸
Rainier Clinical Research Center, Renton, Washington, United States

and more 3 locations

Phase 2, Randomized, Open-Label, Crossover, PD/PK Study of a Novel Pram-Insulin Co-Formulation in Adults With T1D

Phase 2

Completed

Conditions: Diabetes Mellitus, Type 1
Insulin-dependent Diabetes Mellitus

Interventions: Drug: PRAM9
Drug: Regular Insulin + Pramlintide
Drug: Regular Insulin

First Posted Date: 2019-08-30

Last Posted Date: 2024-03-27

Lead Sponsor: Xeris Pharmaceuticals

Target Recruit Count: 18

Registration Number: NCT04074317

Locations: 🇺🇸
World Wide Clinical Trials, San Antonio, Texas, United States

Glucagon Ready-to-Use (RTU) for Prevention of Exercise-Induced Hypoglycemia During Aerobic Exercise in Adults With T1D

Phase 2

Completed

Conditions: Hypoglycemia

Interventions: Drug: Glucagon RTU Injection With Insulin Pump Reduction
Drug: Glugaon RTU Injection Without Insulin Pump Reduction
Other: Vehicle for Glucagon RTU Injection With Insulin Pump Reduction

First Posted Date: 2019-02-15

Last Posted Date: 2023-08-25

Lead Sponsor: Xeris Pharmaceuticals

Target Recruit Count: 48

Registration Number: NCT03841526

Locations: 🇨🇦
LMC Clinical Research Inc, Toronto, Ontario, Canada

Glucagon Ready to Use (RTU) in Subjects With Hyperinsulinemic Hypoglycemia After Bariatric Surgery

Phase 2

Completed

Conditions: Hyperinsulinemic Hypoglycemia

Interventions: Drug: Glucagon RTU
Other: Placebo

First Posted Date: 2018-12-10

Last Posted Date: 2020-05-21

Lead Sponsor: Xeris Pharmaceuticals

Target Recruit Count: 14

Registration Number: NCT03770637

Locations: 🇺🇸
University of Colorado-Denver, Aurora, Colorado, United States
🇺🇸
Mayo Clinic- Rochester, Rochester, Minnesota, United States
🇺🇸
Duke Early Phase Clinical Research, Durham, North Carolina, United States

and more 2 locations

G-Pen Compared to Glucagen Hypokit for Severe Hypoglycemia Rescue in Adults With Type 1 Diabetes

Phase 3

Completed

Conditions: Insulin Hypoglycemia
Type 1 Diabetes Mellitus
Severe Hypoglycemia

Interventions: Drug: G-Pen
Drug: Novo Glucagon

First Posted Date: 2018-11-13

Last Posted Date: 2020-05-22

Lead Sponsor: Xeris Pharmaceuticals

Target Recruit Count: 132

Registration Number: NCT03738865

Locations: 🇦🇹
Medizinische Universität Graz-Center for Medical Research, Graz, Austria
🇺🇸
PPD-Las Vegas Clinical Research Unit, Las Vegas, Nevada, United States
🇨🇦
AltaSciences, Montréal, Quebec, Canada

and more 4 locations

Glucagon Infusion in T1D Patients With Recurrent Severe Hypoglycemia: Effects on Counter-Regulatory Responses

Phase 2

Terminated

Conditions: Hypoglycemia Unawareness
Diabetes Mellitus, Type 1

Interventions: Drug: Placebo
Drug: Glucagon

First Posted Date: 2018-04-06

Last Posted Date: 2021-02-21

Lead Sponsor: Xeris Pharmaceuticals

Target Recruit Count: 49

Registration Number: NCT03490942

Locations: 🇺🇸
University of Alabama, Birmingham, Birmingham, Alabama, United States
🇺🇸
University of California, San Diego, San Diego, California, United States
🇺🇸
Emory University - Grady Memorial Hospital, Atlanta, Georgia, United States

and more 2 locations

G-Pen™ Compared to Lilly Glucagon for Hypoglycemia Rescue in Adults With Type 1 Diabetes

Phase 3

Completed

Conditions: Type 1 Diabetes Mellitus
Severe Hypoglycemia
Insulin Hypoglycemia

Interventions: Drug: G-Pen
Drug: Lilly Glucagon

First Posted Date: 2018-02-20

Last Posted Date: 2020-02-17

Lead Sponsor: Xeris Pharmaceuticals

Target Recruit Count: 81

Registration Number: NCT03439072

Locations: 🇺🇸
ProSciento, Inc., Chula Vista, California, United States
🇺🇸
Atlanta Diabetes Associates, Atlanta, Georgia, United States
🇺🇸
Diablo Clinical Research, Inc., Walnut Creek, California, United States

and more 3 locations

Glucose Response of G-Pen (Glucagon Injection) in Pediatric T1D Patients

Phase 3

Completed

Conditions: Diabetes Mellitus, Type 1

Interventions: Drug: Glucagon

First Posted Date: 2017-03-27

Last Posted Date: 2018-12-11

Lead Sponsor: Xeris Pharmaceuticals

Target Recruit Count: 31

Registration Number: NCT03091673

Locations: 🇺🇸
University of Florida, Gainesville, Florida, United States
🇺🇸
University of Iowa, Iowa City, Iowa, United States
🇺🇸
Indiana University, Indianapolis, Indiana, United States

and more 4 locations

CSI-Glucagon for Prevention of Hypoglycemia in Children With Congenital Hyperinsulinism

Phase 2

Completed

Conditions: Congenital Hyperinsulinism

Interventions: Drug: Glucagon
Other: Placebo

First Posted Date: 2016-10-18

Last Posted Date: 2019-12-10

Lead Sponsor: Xeris Pharmaceuticals

Target Recruit Count: 5

Registration Number: NCT02937558

Locations: 🇺🇸
UCSF School of Medicine, Division of Pediatric Endocrinology, San Francisco, California, United States
🇺🇸
Washington University, St. Louis Children's Hospital, Saint Louis, Missouri, United States
🇺🇸
UCLA Mattel Children's Hospital, Los Angeles, California, United States

and more 2 locations

Delivery of G-Pump™ (Glucagon Infusion) From an OmniPod® to Prevent Hypoglycemia in Post-Bariatric Surgery Patients

Phase 2

Completed

Conditions: Complications of Bariatric Procedures
Hypoglycemia

Interventions: Drug: G-Pump™ (glucagon infusion)

First Posted Date: 2016-04-11

Last Posted Date: 2018-10-30

Lead Sponsor: Xeris Pharmaceuticals

Target Recruit Count: 8

Registration Number: NCT02733588

Locations: 🇺🇸
Joslin Diabetes Center, Boston, Massachusetts, United States

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy